D-erythro-dihydrosphingosine suppresses melanoma growth and induces caspase-dependent GSDME-mediated pyroptosis
Year: 2026
Type: article
Abstract: Background Melanoma is an aggressive skin malignancy characterized by high metastatic potential and therapeutic resistance, highlighting the need for candidate agents with distinct mechanisms of tumor-cell killing. D-erythro-dihydrosphingosine (DES), a naturally occurring sphingoid base, has not been well characterized in melanoma. Methods In this study, we investigated the anti-melanoma activity of DES and its underlying cell-death mechanism. Results DES reduced A375 cell viability in a concentration-dependent manner, with an IC 50 of approximately 0.5701 μM, and induced progressive membrane-disruptive morphological changes and LDH release. Similar morphological alterations and GSDME cleavage were observed in SK-MEL-28 cells. The pan-caspase inhibitor Z-VAD-FMK markedly attenuated DES-induced membrane damage and GSDME cleavage. DES also promoted PARP cleavage and activation of caspase-3 and caspase-9 together with accumulation of the pore-forming GSDME-N fragment. Importantly, depletion of GSDME using two independent knockdown constructs substantially reduced DES-induced LDH release and restored cell viability, providing functional evidence that GSDME contributes to DES-induced melanoma-cell death. In a melanoma xenograft model, DES significantly suppressed tumor growth and was accompanied by increased GSDME-N, cleaved caspase-3, cleaved caspase-9, and cleaved PARP in tumor tissues. No marked changes in body weight, serum ALT, AST, CK-MB, or BUN levels, or major-organ histopathology were observed at the tested doses. Exploratory network pharmacology, molecular docking, and molecular dynamics simulations further nominated EGFR as a candidate DES-associated protein. Conclusions Collectively, these findings demonstrate that DES exerts anti-melanoma activity and induces caspase-associated, GSDME-dependent pyroptotic cell death, supporting its further investigation as a candidate anti-melanoma agent.
Source: Frontiers in Oncology
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $3,801
OpenAlex ID: W7236835889
